Top

Published in:

Open Access 01-07-2009 | Comment

Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas

Authors: Olga Balague Ponz, German Ott, Robert P. Hasserjian, Kojo S. J. Elenitoba-Johnson, Laurence de Leval, Daphne de Jong

Published in: Journal of Hematopathology | Issue 2/2009

Abstract

In the novel WHO classification 2008, the classification of aggressive B-cell lymphoma has been revised for several categories with the aim to define “clean” entities. Within large B-cell lymphoma, a few distinct clinico-pathological entities have been recognized with more clinically defined entities than pathologically defined ones. The majority of known morphological variations were not considered to merit more than classification as a variant of DLBCL, not otherwise specified. Specifically, a biological subgrouping of DLBCL on the basis of molecular (activated B-cell versus germinal center B-cell) or immunophenotypic (CD5+) features was felt to be too immature to include at this stage. The role of EBV in aggressive B-cell lymphoma has been explored in more depth with the recognition of several novel and re-defined clinico-pathological entities. Also, in these diseases, clinical definitions play a very dominant role in the WHO classification 2008.

Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of tumors of hematopoietic and lymphoid tissues. IARC, Lyon

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRef

Yamaguchi M, Seto M, Okamoto M et al (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821PubMedCrossRef

Yamaguchi M, Nakamura N, Suzuki R et al (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195–1202PubMedCrossRef

de JD, Xie W, Rosenwald A et al (2009) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 62:128–138

Booman M, Douwes J, Glas AM et al (2006) Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-Cell lymphoma. Clin Cancer Res 12:2698–2705PubMedCrossRef

Kuppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3:801–812PubMedCrossRef

Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74:9964–9971PubMedCrossRef

Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406–1412PubMed

10.

Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130–2136PubMedCrossRef

11.

Oksenhendler E, Boulanger E, Galicier L et al (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331–2336PubMedCrossRef

12.

Colomo L, Loong F, Rives S et al (2004) Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28:736–747PubMedCrossRef

13.

Gaidano G, Cerri M, Capello D et al (2002) Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol 119:622–628PubMedCrossRef

14.

Kanno H, Ohsawa M, Hashimoto M et al (1999) HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas. Int J Cancer 82:630–634PubMedCrossRef

15.

Mauray S, Fuzzati-Armentero MT, Trouillet P et al (2000) Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 30:2065–2073PubMedCrossRef

Title: Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas
Authors: Olga Balague Ponz
German Ott
Robert P. Hasserjian
Kojo S. J. Elenitoba-Johnson
Laurence de Leval
Daphne de Jong
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Journal of Hematopathology / Issue 2/2009
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-009-0038-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule

Recent advances in bone marrow biopsy pathology

Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms

T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary

Commentary on the WHO 2008 classification of neoplasms arising from histiocytic and other accessory cells

Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma